What is Equillium?
Equillium is a clinical-stage biotechnology firm dedicated to addressing critical unmet medical needs in the United States through the development of innovative treatments for severe autoimmune and inflammatory conditions. The company's focus on immuno-inflammatory disorders positions it within a key segment of the biopharmaceutical market, aiming to bring novel solutions to patients suffering from debilitating diseases.
How much funding has Equillium raised?
Equillium has raised a total of $100M across 3 funding rounds:
Share Placement
$15M
Stock/Share Issuance
$50M
Stock/Share Issuance
$35M
Share Placement (2020): $15M with participation from Lincoln Park Capital Fund , LLC
Stock/Share Issuance (2025): $50M led by Woodline Partners, Adage Capital Management, and Janus Henderson Investors
Stock/Share Issuance (2026): $35M supported by RA Capital Management
Key Investors in Equillium
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools. The company also has a growing interest in climate and sustainability technologies. RA Capital aims to partner with innovators to bring ideas from the lab to the clinic, ultimately improving patient lives. Their internal think tank, TechAtlas, analyzes scientific and clinical data to support their investment strategies.
Janus Henderson Investors
Janus Henderson is a global investment management firm that provides a broad range of investment solutions and advisory services to institutional investors, financial professionals, and individual clients. The company is focused on helping clients achieve their financial objectives through disciplined investment strategies, in-depth research, and a commitment to delivering strong long-term outcomes. By combining global market expertise with a client-centric approach, it seeks to create investment solutions that address diverse financial goals and evolving market conditions.
Woodline Partners
San Francisco-based Woodline Partners LP ("Woodline") is an investment firm implementing a market neutral equity strategy, focused on the global Healthcare and Technology sectors. Woodline's sub-sector Portfolio Manager model enables a focus on generating idiosyncratic alpha and avoiding systemic risk factors.
What's next for Equillium?
The recent major strategic investment signals a pivotal growth phase for Equillium, likely enabling the acceleration of its clinical development pipeline and the expansion of its research initiatives. This influx of capital is expected to bolster the company's efforts in bringing its therapeutic candidates through further clinical trials and towards potential commercialization, reinforcing its commitment to advancing patient care in the autoimmune and inflammatory disease landscape.
See full Equillium company page
